Growth, detection, quantification, and inactivation of SARS-CoV-2
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is the agent responsible for the coronavirus disease 2019 (COVID-19) global pandemic. SARS-CoV-2 is closely related to SARS-CoV, which caused the 2003 SARS outbreak. Although numerous reagents were developed to study SARS-CoV infections, few have been applicable to evaluating SARS-CoV-2 infection and immunity. Current limitations in studying SARS-CoV-2 include few validated assays with fully replication-competent wild-type virus. We have developed protocols to propagate, quantify, and work with infectious SARS-CoV-2. Here, we describe: (1) virus stock generation, (2) RT-qPCR quantification of SARS-CoV-2 RNA; (3) detection of SARS-CoV-2 antigen by flow cytometry, (4) quantification of infectious SARS-CoV-2 by focus-forming and plaque assays; and (5) validated protocols for virus inactivation. Collectively, these methods can be adapted to a variety of experimental designs, which should accelerate our understanding of SARS-CoV-2 biology and the development of effective countermeasures against COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 4×
“Although the S protein of SARS-CoV and SARS-CoV-2 are structurally similar (Li et al., 2005; Walls et al., 2020; Wrapp et al., 2020), genetically similar (Walls et al.”
InfluentialStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · cited 5×
“However, polyclonal sera from mice immunized with recombinant SARS-CoV RBD protein inhibits SARSCoV-2 infection (Walls et al., 2020).”
InfluentialAngiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 3×
“, 2020), and use the same receptor (Lei et al., 2020; Li et al., 2003), neutralizing anti-SARS-CoV RBD antibodies (Abs) generally lack cross-reactivity to SARS-CoV-2 (Wrapp et al.”
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · cited 2×
“This limitation has compelled the development of many in vitro assays that utilize heterologous pseudotyped viruses expressing the SARS-CoV-2 S protein (Lei et al., 2020; Letko et al., 2020).”
Rockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., & Baric, R. (2008) · Journal of Virology · doi:10.1128/jvi.02377-07 · Cited by 134 · cited 1×
“The S protein also is a key target for neutralizing antibodies and vaccine strategies (Rockx et al., 2008; Sui et al., 2005; Zhu et al., 2007).”
Cited by
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Halfmann, P. J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 694
Self-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651
SARS-CoV-2 viral load and shedding kinetics
Puhach, O., Meyer, B., & Eckerle, I. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00822-w · Cited by 424
Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.026 · Cited by 366
Self-citationPuhach, O., Adea, K., Hulo, N., Sattonnet, P., Genecand, C., Iten, A., Jacquérioz, F., Kaiser, L., Vetter, P., Eckerle, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01816-0 · Cited by 372
Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.029 · Cited by 362
Self-citationThe total number and mass of SARS-CoV-2 virions
Sender, R., Bar-On, Y. M., Gleizer, S., Bernshtein, B., Flamholz, A., Phillips, R., & Milo, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024815118 · Cited by 275
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
Uraki, R., Kiso, M., Iida, S., Imai, M., Takashita, E., Kuroda, M., Halfmann, P. J., Loeber, S., Maemura, T., Yamayoshi, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04856-1 · Cited by 273
Self-citationSARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis
Bailey, A. L., Dmytrenko, O., Greenberg, L., Bredemeyer, A. L., Ma, P., Liu, J., Penna, V., Winkler, E. S., Sviben, S., Brooks, E., et al. (2021) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2021.01.002 · Cited by 193
Self-citationThe duration of infectiousness of individuals infected with SARS-CoV-2
Walsh, K. A., Spillane, S., Comber, L., Cardwell, K., Harrington, P., Connell, J., Teljeur, C., Broderick, N., de Gascun, C. F., Smith, S. M., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.10.009 · Cited by 157
Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169
Self-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651
Ku, M.-W., Bourgine, M., Authié, P., Lopez, J., Nemirov, K., Moncoq, F., Noirat, A., Vesin, B., Nevo, F., Blanc, C., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.12.010 · Cited by 139
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
van Breemen, R. B., Muchiri, R. N., Bates, T. A., Weinstein, J. B., Leier, H. C., Farley, S., & Tafesse, F. G. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00946 · Cited by 135
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
Self-citationSuryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · doi:10.1101/2021.01.19.427324 · Cited by 361
Self-citationCase, J. B., Chen, R. E., Cao, L., Ying, B., Winkler, E. S., Johnson, M., Goreshnik, I., Pham, M. N., Shrihari, S., Kafai, N. M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.008 · Cited by 73
Self-citationCruz Tleugabulova, M., Melo, S. P., Wong, A., Arlantico, A., Liu, M., Webster, J. D., Lau, J., Lechner, A., Corak, B., Hodgins, J. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53700-9 · Cited by 38
Self-citation
Metadata
- Authors
- Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E., & Diamond, M. S.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 548
- Pages
- 39-48
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W3035628751
- Cited by
- 245
- References
- 6
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.